Latest Insider Transactions at Mineralys Therapeutics, Inc. (MLYS)
This section provides a real-time view of insider transactions for Mineralys Therapeutics, Inc. (MLYS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mineralys Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mineralys Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.32%
|
$0
$0.54 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,026
-3.44%
|
$75,390
$15.0 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,043
+3.38%
|
$0
$0.81 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,482
-15.78%
|
$382,230
$15.03 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,482
+13.63%
|
$25,482
$1.08 P/Share
|
|
Oct 14
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,352
+3.79%
|
$5,352
$1.08 P/Share
|
|
Oct 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,271
-1.68%
|
$198,523
$13.52 P/Share
|
|
Oct 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.7%
|
$0
$0.54 P/Share
|
|
Oct 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.34%
|
$139,841
$13.57 P/Share
|
|
Sep 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+4.81%
|
$6,349
$1.08 P/Share
|
|
Sep 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,018
+4.04%
|
$0
$0.54 P/Share
|
|
Aug 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,365
+4.85%
|
$0
$0.81 P/Share
|
|
Jul 24
2024
|
Brian Taylor Slingsby Director |
SELL
Open market or private sale
|
Indirect |
550,000
-5.98%
|
$7,150,000
$13.05 P/Share
|
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
525
-0.51%
|
$7,875
$15.0 P/Share
|
|
Jul 16
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
525
+0.51%
|
$525
$1.08 P/Share
|
|
Jul 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.81%
|
$6,349
$1.08 P/Share
|
|
Jul 11
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,746
-1.7%
|
$204,698
$13.34 P/Share
|
|
Jul 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.16%
|
$139,841
$13.14 P/Share
|
|
Jul 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+4.94%
|
$0
$0.54 P/Share
|
|
Jun 20
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,940
-1.59%
|
$164,340
$11.73 P/Share
|
|
Jun 18
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,607
-1.73%
|
$182,677
$11.99 P/Share
|
|
Jun 17
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,766
-1.82%
|
$213,192
$12.25 P/Share
|
|
Jun 14
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,229
-1.64%
|
$194,748
$12.52 P/Share
|
|
Jun 13
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
39,961
-3.87%
|
$479,532
$12.74 P/Share
|
|
Jun 12
2024
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,607
-1.58%
|
$199,284
$12.77 P/Share
|
|
Jun 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+6.61%
|
$6,349
$1.08 P/Share
|
|
Jun 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+5.68%
|
$0
$0.54 P/Share
|
|
Jun 11
2024
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
96,815
-27.48%
|
$1,161,780
$12.94 P/Share
|
|
May 13
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,366
+7.0%
|
$0
$0.81 P/Share
|
|
May 09
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.15%
|
$1,500
$15.0 P/Share
|
|
May 09
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.15%
|
$100
$1.08 P/Share
|
|
Apr 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+8.66%
|
$6,349
$1.08 P/Share
|
|
Apr 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+7.64%
|
$0
$0.54 P/Share
|
|
Mar 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+10.24%
|
$6,348
$1.08 P/Share
|
|
Mar 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+9.24%
|
$0
$0.54 P/Share
|
|
Feb 12
2024
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Indirect |
555,555
+9.87%
|
$7,222,215
$13.5 P/Share
|
|
Feb 12
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
1,672,508
+35.92%
|
$21,742,604
$13.5 P/Share
|
|
Feb 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,366
+12.11%
|
$0
$0.81 P/Share
|
|
Jan 12
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+16.17%
|
$6,348
$1.08 P/Share
|
|
Jan 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+15.89%
|
$0
$0.54 P/Share
|
|
Dec 11
2023
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,018
+20.0%
|
$0
$0.54 P/Share
|
|
Nov 22
2023
|
Jon Congleton Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,250
+0.4%
|
$21,250
$5.97 P/Share
|
|
Nov 13
2023
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+25.0%
|
$0
$0.54 P/Share
|
|
Nov 03
2023
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,034
+50.0%
|
$0
$0.54 P/Share
|
|
Sep 06
2023
|
Jon Congleton Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,250
+0.21%
|
$27,000
$12.08 P/Share
|
|
Aug 17
2023
|
Jon Congleton Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,250
+0.22%
|
$27,000
$12.1 P/Share
|
|
Aug 11
2023
|
Jon Congleton Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.19%
|
$24,000
$12.89 P/Share
|
|
Aug 11
2023
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
157,091
-100.0%
|
$1,885,092
$12.81 P/Share
|
|
Aug 11
2023
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
157,091
+50.0%
|
$0
$0.81 P/Share
|